110942-02-4

Basic information

• Product Name: HUMAN IL-2
• Synonyms: HUMAN ALDESLEUKIN;HIL-2;IL-2 HUMAN, NATURAL;IL-2, HUMAN;IL-2;HUMAN T-CELL GROWTH FACTOR;HUMAN TCGF;HUMAN IL-2
• CAS NO: 110942-02-4
• Molecular Weight: 0
• Product Categories: monoclonal antibody
• Mol File: 110942-02-4.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Storage Temp.: −70°C
• CAS DataBase Reference: HUMAN IL-2(CAS DataBase Reference)
• NIST Chemistry Reference: HUMAN IL-2(110942-02-4)
• EPA Substance Registry System: HUMAN IL-2(110942-02-4)

Safety Data

• Hazard Codes: B,Xi
• Statements: 36
• Safety Statements: 23-24/25-26
• WGK Germany: 3
• RTECS: NM9741332
• Hazardous Substances Data: 110942-02-4(Hazardous Substances Data)

Usage

Description

HUMAN IL-2, also known as Aldesleukin or Proleukin, is a recombinant DNA-derived lymphokine that is structurally similar to native interleukin-2 (IL-2) but has biological activity comparable to the natural lymphokine. It is primarily produced by peripheral blood lymphocytes and contains 133 amino acid residues. HUMAN IL-2 plays a crucial role in the immune system by enhancing lymphocyte mitogenesis, stimulating the growth of IL-2-dependent cell lines, enhancing cytotoxicity of lymphocytes, inducing lymphokine-activated killer (LAK) cells and NK cells, and inducing interferon production.

Uses

Used in Antineoplastic Applications:
HUMAN IL-2 is used as an antineoplastic agent for the treatment of adult metastatic renal cell carcinoma and metastatic melanoma. It modulates the immune system to target and destroy cancer cells, making it a valuable tool in cancer therapy.
Used in Immunostimulant Applications:
HUMAN IL-2 is used as an immunostimulant to enhance the immune response in patients with various cancers. It stimulates the growth and activity of immune cells, such as T lymphocytes, NK cells, and LAK cells, which can help the body fight off cancer cells more effectively.
Used in Biological Response Modifier Applications:
HUMAN IL-2 is used as a biological response modifier to alter the body's immune response to cancer. It activates cellular immunity in patients, leading to profound lymphocytosis, eosinophilia, and thrombocytopenia. This can help the immune system recognize and attack cancer cells more effectively.
Used in Research and Diagnostic Applications:
HUMAN IL-2 is used in the production of tumor-specific cytotoxic T lymphocytes, the stimulation of human primary naive T lymphocytes, and the detection of IL-2 using a 4-Fluoro-3-nitrophenyl grafted gold electrode-based platform. These applications are crucial for studying the effects of IL-2 on cell death and immune cell proliferation, as well as for developing new diagnostic tools and therapies for cancer treatment.
Used in Drug Development and Treatment of Various Cancers:
Research is underway on the use of HUMAN IL-2 for the treatment of various cancers, including head and neck cancers, acute myelogenous leukemia, and as adjunct therapy in the treatment of Kaposi sarcoma. Its role in enhancing the immune response and stimulating the growth of immune cells makes it a promising candidate for further development and application in cancer treatment.

Indications

Aldesleukin (IL-2, Proleukin) is a human recombinant interleukin-2 protein. Its antitumor action is thought to include multiple effects on the immune system, such as enhancement of T-lymphocyte cytotoxicity, induction of natural killer cell activity, and induction of interferon-γ production. Aldesleukin has been used alone and in combination with lymphokine activated killer (LAK) cells or tumor-infiltrating lymphocytes (TIL). The drug produces remissions in 15% of patients with renal cell carcinoma, with median durations of remission of 18 to 24 months.

Biochem/physiol Actions

Interleukin-2 (IL-2) is an immunomodulatory factor produced by certain subsets of T lymphocytes. This lymphokine promotes long-term growth of activated T cells and related cell types. IL-2 plays a role in the activation and proliferation of natural killer cells, induces γ-interferon and B cell growth factor secretion, and modulates the expression of the IL-2 receptor. IL-2 expression is known to reduce with age and results in influenza infection, neoplasms and lethal autoimmunity. IL-2 participates in T cell proliferation and differentiation and controls the homeostasis of T cell. As a part of immune response, IL-2 stimulates the action of T helper cell 1 and 2 along with endothelial white blood cells of skeletal muscles. IL-2 regulation is controlled by c-rel protein. IL-2 is a neurotrophic molecule and has special functions in cortical, hippocampal, septal, cerebellar and retinal neurons.

Clinical Use

Recombinant interleukin-2 Treatment of metastatic renal cell carcinoma

Side effects

Several serious toxicities have been observed, with a fatality rate of 5% in the initial studies. The major adverse effect is severe hypotension in as many as 85% of patients, which may lead to myocardial infarctions, pulmonary edema, and strokes.This hypotension is thought to be due to a capillary leak syndrome resulting from extravasation of plasma proteins and fluid into extravascular space and a loss of vascular tone. Patients with significant cardiac, pulmonary, renal, hepatic, or CNS conditions should not receive therapy with aldesleukin. Other adverse reactions include nausea and vomiting, diarrhea, stomatitis, anorexia, altered mental status, fevers, and fatigue.

Drug interactions

Potentially hazardous interactions with other drugs Corticosteroids: avoid concomitant use. Cytotoxics: avoid concomitant use with cisplatin, dacarbazine and vinblastine.

Metabolism

Greater than 80% of aldesleukin distributed to plasma, cleared from the circulation and presented to the kidney is metabolised to amino acids in the cells lining the proximal convoluted tubules. A secondary elimination pathway is IL-2 receptor- mediated uptake.

Related news

Full paperRecombinant Newcastle disease virus (NDV/Anh-IL-2) expressing HUMAN IL-2 (cas 110942-02-4) as a potential candidate for suppresses growth of hepatoma therapy08/28/2019

Newcastle disease virus (NDV) have shown oncolytic therapeutic efficacy in preclinical study and are currently approved for clinical trials. NDV Anhinga strain which is a mesogenic strain should be classified as lytic strain and has a therapeutic efficacy in hepatocellular cancer. In this study,...detailed

Research paperDiphtheria toxin-based bivalent HUMAN IL-2 (cas 110942-02-4) fusion toxin with improved efficacy for targeting human CD25+ cells08/24/2019

Regulatory T cells (Treg) constitute a major inhibitory cell population which suppresses immune responses. Thus, Treg have proven to be key players in the induction of transplantation tolerance, protection from autoimmune disease and prevention of the development of effective anti-tumor immune r...detailed

Ontak-like HUMAN IL-2 (cas 110942-02-4) fusion toxin08/21/2019

Ontak® is a FDA-approved diphtheria toxin-based recombinant fusion toxin for treatment of human CD25+ cutaneous T cell lymphoma (CTCL). However, it has been discontinued clinically due to the production issue related to the bacterial expression system with difficult purification. Recently we hav...detailed